GTx, Inc. (NASDAQ: GTXI) today announced that clinical data from two separate enobosarm clinical development programs will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30 - June 3, 2014, in Chicago, Illinois.
Enobosarm 9mg: for the potential treatment of androgen receptor and estrogen receptor positive metastatic breast cancer
New top-line results from an ongoing Phase 2, open label clinical study evaluating an oral daily dose of 9mg enobosarm for the treatment of androgen receptor (AR) positive and estrogen receptor (ER) positive metastatic breast cancer in women who have previously responded to hormonal therapy for the treatment of their advanced breast cancer, will be presented at a poster session as follows:
Title: | Enobosarm: A targeted therapy for metastatic, androgen receptor positive, breast cancer | |||
Presenter: | Beth Overmoyer, M.D., Director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School | |||
Session: | Breast Cancer – HER2/ER | |||
Date: | Monday, June 2, 8:00-11:45 a.m. CT | |||
Location: | S Hall A2 | |||
Enobosarm 3mg: for the potential prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer (NSCLC)
Results from the POWER1 (platinum plus taxane) and POWER2 (platinum plus non-taxane) Phase 3 clinical trials evaluating enobosarm 3mg for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer (NSCLC) will be presented at a poster session. While the findings of these pivotal trials have been previously discussed, this presentation reiterates that enobosarm had a significant effect on lean body mass.
Title: | Enobosarm and lean body mass in patients with non-small cell lung cancer | |||
Presenter: | Jeffrey Crawford, M.D., Chief, Division of Medical Oncology at Duke University School of Medicine, and principal investigator for the POWER1 and POWER2 trials | |||
Session: | Patient and Survivor Care | |||
Date: | Sunday, June 1, 8:00-11:45 a.m. CT | |||
Location: | S Hall A2 | |||
Copies of the posters will be available by contacting the Company.
About GTx
GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, including prevention and treatment of cancer-related muscle wasting, and other serious medical conditions.
Forward-Looking Information is Subject to Risk and Uncertainty
This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, statements relating to GTx's clinical trials for enobosarm (GTx-024). GTx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks (i) that GTx may not be able to obtain required regulatory approvals to commercialize its product candidates in a timely manner or at all; or (ii) that clinical trials being conducted by GTx may not be completed on schedule, or at all, or may otherwise be suspended or terminated. GTx’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. GTx will continue to need additional funding and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product candidate development programs and potentially cease operations. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2014 contains under the heading, "Risk Factors", a more comprehensive description of these and other risks to which GTx is subject. GTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Contacts:
BrewLife
Denise Powell, 510-703-9491
dpowell@brewlife.com
or
Investors:
GTx,
Inc.
Marc Hanover, 901-507-6915
Interim CEO, President and
Chief Operating Officer
mhanover@gtxinc.com